Vii Lpmdv Ix Lp Seventh Mdv... Net Worth

The estimated Net Worth of Vii Lpmdv Ix Lp Seventh Mdv... is at least $211 millier dollars as of 15 April 2014. Vii Mdv owns over 300,000 units of Adamas Pharmaceuticals Inc stock worth over $210,933 and over the last 10 years Vii sold ADMS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Vii Mdv ADMS stock SEC Form 4 insiders trading

Vii has made over 1 trades of the Adamas Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Vii bought 300,000 units of ADMS stock worth $4,800,000 on 15 April 2014.

The largest trade Vii's ever made was buying 300,000 units of Adamas Pharmaceuticals Inc stock on 15 April 2014 worth over $4,800,000. On average, Vii trades about 300,000 units every 0 days since 2014. As of 15 April 2014 Vii still owns at least 25,661 units of Adamas Pharmaceuticals Inc stock.

You can see the complete history of Vii Mdv stock trades at the bottom of the page.

Insiders trading at Adamas Pharmaceuticals Inc

Over the last 10 years, insiders at Adamas Pharmaceuticals Inc have traded over $26,222,162 worth of Adamas Pharmaceuticals Inc stock and bought 1,128,061 units worth $17,799,399 . The most active insiders traders include Point Partners Llcjay Jeffr..., David L Mahoney et William W. Ericson. On average, Adamas Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of $254,236. The most recent stock trade was executed by Vijay Shreedhar on 21 June 2021, trading 6,200 units of ADMS stock currently worth $31,992.

What does Adamas Pharmaceuticals Inc do?

Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

Complete history of Vii Mdv stock trades at Adamas Pharmaceuticals Inc

Adamas Pharmaceuticals Inc executives and stock owners

Adamas Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Neil McFarlane,
  Chief Executive Officer, Director
• Vijay Shreedhar,
  Chief Commercial Officer
• Christopher Prentiss,
  Chief Financial Officer, Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer
• David Mahoney,
  Lead Independent Chairman of the Board
• Martha Demski,
  Independent Director
• William Ericson,
  Independent Director
• Michael Bigham,
  Independent Director
• Mardi Dier,
  Independent Director
• Ivan Lieberburg,
  Independent Director
• John MacPhee,
  Director
• Anna Richo,
  Director
• Adrian Quartel,
  Chief Medical Officer
• Adrian Quartel M.D.,
  Chief Medical Officer
• Eric C. Schlezinger,
  Head of HR
• Dr. Jill M. Jene,
  Head of Corp. Devel., Strategy , Portfolio Planning & Alliance Management
• Sarah Mathieson,
  Head of Corp. Communications, Patient Advocacy & Engagement
• Richard H Booth,
  Director
• Rajiv Patni,
  Chief Medical Officer
• Ix Lp Seventh Mdv Partners,...,
  
• William J Dawson,
  Chief Financial Officer
• Natalie Mc Clure,
  SVP, Product Development
• Point Partners Llcjay Jeffr...,
  
• Richard King,
  Chief Operating Officer
• Gregory T Went,
  Chief Executive Officer
• Alfred G Merriweather,
  Chief Financial Officer
• Jennifer J Rhodes,
  General Counsel
• Capital Equity Investments,...,
  10% owner
• Sara Grootwassink Lewis,
  Director
• Jeffrey H Knapp,
  Chief Operating Officer
• Grace Shin,
  General Counsel
• Vii Lpmdv Ix Lp Seventh Mdv...,
  
• Ventures Management Iii, Ll...,
  
• Spyros Papapetropoulos,
  Director